An Open-label Pilot Study of the Effect of Second-line Treatment With Herceptin Monotherapy on Time to Disease Progression in Patients With Metastatic Urothelial Cancer and HER2 Overexpression

Trial Profile

An Open-label Pilot Study of the Effect of Second-line Treatment With Herceptin Monotherapy on Time to Disease Progression in Patients With Metastatic Urothelial Cancer and HER2 Overexpression

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2014

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 19 Dec 2013 New source identified and integrated, ClinicalTrials.gov record.
    • 23 Feb 2010 Status changed from recruiting to completed as reported by Roche record
    • 23 Jul 2009 Status changed from active, no longer recruiting to recruiting as reported by Roche record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top